GHGuardant Health Inc
GH
Guardant Health Inc4,914
Mkt Cap
$15.77BVolume
2.82M52W High
$121.0152W Low
$37.73PE Ratio
-34.98GH Fundamentals
Price
$118.95Prev Close
$118.01Open
$119.0650D MA
$91.17Beta
1.39Avg. Volume
2.2MEPS (Annual)
-$3.32P/B
-86.39Rev/Employee
$391,867.92$13,314.24
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians...
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardants Board of Directors approved the granting of...
Guardant Health (GH) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the...
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +16.44% and +16.96%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +24.97% and +1.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health Receives FDA Approval for Guardant360 CDx as a Companion Diagnostic for Arvinas and Pfizers VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360 CDx liquid biopsy test as a...
Short Interest in Guardant Health, Inc. (NASDAQ:GH) Decreases By 15.0%
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 11,642,109 shares, a decline of 15.0% from the March 31st total of 13,696,676 shares. Based on an average...
<
1
2
...
>
Compact View
Not available
Not available